Cipla Share Price
Mid Cap | Pharmaceuticals and health care | NSE: CIPLA | BSE: 500087
₹1,472.00 
-7.80 (-0.53 %)
Last Updated: 21 Feb 2025 04:01 PM
BEARISH
Overview
Open (₹) 1,489.95
High (₹) 1,501.05
Low (₹) 1,469.80
Prev. Close (₹) 1,479.80
Volume 24,590
VWAP (₹) 1,479.84
ROCE (%) 21.79
Industry P/E 43.99
TTM P/E 23.83
P/B Ratio 4.45
Market Cap (₹) Cr.1,19,183.77
Dividend Yield (%)0.88
EPS (₹) 51.01
ROE15.37%
Sales Growth (%) 13.28
Profit Growth (%)46.55
Day Range
1,501.051,501.05
52 Week Range
1,317.601,702.00
Historical Returns
Returns (6M)
-7.62 %
Returns (1Y)
0.4 %
Returns (3Y)
60.74 %
Returns (5Y)
242.09 %
Returns (6M)
-7.62 %
Returns (1Y)
0.4 %
Returns (3Y)
60.74 %
Returns (5Y)
242.09 %
SWOT Analysis
- Effectively using its capital to generate profits - ROCE improved in the last year
- Company with (47.05%) TTM EPS Growth
- Company with Low Debt
- Book value per share improving over the last 2 years
- Efficient in managing Assets to generate Profits - ROA improved since last year
- Company with 47.05% positive TTM EPS growth
- Increasing Annual Revenue for Past 2 Years
- Growth in Net Profit Margin (QoQ)
- Increasing Revenue every Quarter for the past 4 Quarters
- Strong short-term momentum: Price above short-term moving averages (EMA_10)
- Bullish MACD crossover (12,6,9) indicates potential upward price movement.
- High CCI indicates strong upward momentum.
- Positive ROC (9) indicates upward momentum.
- Price above EMA and SMA (50) indicates bullish momentum.
Technicals
Technical Rating
BEARISHRSI 63.62
MFI 60.21
ATR 33.63
Commodity Channel Index 124.92
ROC125 -6.39
ROC21 4.43
Williams %R -34.16
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 1,493.64 | 1,512.97 | 1,524.89 | 1,481.72 | 1,462.39 | 1,450.47 | 1,431.14 |
| Week Ago | 1,481.25 | 1,503.45 | 1,524.70 | 1,460.00 | 1,437.80 | 1,416.55 | 1,394.35 |
| Month Ago | 1,453.35 | 1,479.40 | 1,494.15 | 1,438.60 | 1,412.55 | 1,397.80 | 1,371.75 |
EMA & SMA
1472.00
Current Price
Bullish Moving Averages
14
Bearish Moving Averages
6
5 Day 1474.18
9 Day 1464.51
10 Day 1465.06
12 Day 1461.01
14 Day 1461.88
20 Day 1453.18
26 Day 1449.90
50 Day 1463.85
100 Day 1504.74
200 Day 1517.93
Deals & Announcements
Bulk and Block Deals
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| BNP PARIBAS ARBITRAGE | block | Sell | 25 Jan, 2024 | ₹1,417.35 | 11,88,318 | BSE |
| SOCIETE GENERALE | block | Buy | 25 Jan, 2024 | ₹1,417.35 | 11,88,318 | BSE |
| JUPITER SOUTH ASIA INVESTMENT COMPANY LIMITED | block | Sell | 18 Jan, 2024 | ₹1,293.50 | 1,42,206 | BSE |
| THE JUPITER GLOBAL FUND-JUPITER INDIA SELECT | block | Buy | 18 Jan, 2024 | ₹1,293.50 | 1,42,206 | BSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 25 Oct, 2022 | ₹1,146.45 | 4,09,513 | BSE |
| ISHARES CORE MSCI EMERGING MARKETS ETF | block | Buy | 25 Oct, 2022 | ₹1,146.45 | 4,09,513 | BSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 17 Oct, 2022 | ₹1,108.90 | 6,43,544 | BSE |
| ISHARES CORE MSCI EMERGING MARKETS ETF | block | Buy | 17 Oct, 2022 | ₹1,108.90 | 6,43,544 | BSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 11 Oct, 2022 | ₹1,118.85 | 6,29,290 | BSE |
| ISHARES CORE MSCI EMERGING MARKETS ETF | block | Buy | 11 Oct, 2022 | ₹1,118.85 | 6,29,290 | BSE |
| Y K HAMIED | bulk | Sell | 15 Feb, 2022 | ₹910.05 | 1,34,46,504 | BSE |
| M K HAMIED | bulk | Sell | 15 Feb, 2022 | ₹910.15 | 67,23,252 | BSE |
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 22 Aug, 2024 | Anusha Jain | Disposal | ₹1,590.8315 | 2,000 | BSE |
| 14 Aug, 2024 | Anusha Jain | Disposal | ₹1,587.95 | 3,000 | BSE |
| 18 Oct, 2023 | Priyanka Mallick | Acquisition | ₹1,273.28 | 500 | BSE |
| 18 Oct, 2023 | Jaideep Mallick | Acquisition | ₹1,269.80 | 150 | BSE |
| 18 Oct, 2023 | Priyanka Mallick | Acquisition | ₹1,186.675 | 200 | BSE |
| 13 Apr, 2023 | Vidya Prabhakar Rote jointly with Kiran Rote | Acquisition | ₹1,110.38 | 1,000 | BSE |
| 13 Apr, 2023 | Vidya Prabhakar Rote jointly with Kiran Rote | Revoke | ₹1,075.90 | 1,000 | BSE |
| 13 Apr, 2023 | Vidya Prabhakar Rote jointly with Kiran Rote | Pledge | ₹1,119.15 | 1,000 | BSE |
| 05 Apr, 2023 | Shachi Malpani | Pledge | ₹965.95 | 10,000 | BSE |
| 05 Apr, 2023 | Shachi Malpani | Acquisition | ₹1,021.95 | 10,000 | BSE |
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 10 May, 2024 | Rs.13.0000 per share(650%)Final Dividend | 02 Aug, 2024 | 02 Aug, 2024 |
| 12 May, 2023 | Rs.8.5000 per share(425%)Final Dividend | 21 Jul, 2023 | 21 Jul, 2023 |
| 27 Jul, 2022 | Rs.5.0000 per share(250%)Dividend | 08 Aug, 2022 | 10 Aug, 2022 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 20 Feb, 2025 | BSE India | USFDA inspection at analytical testing facility of Sitec Labs Limited in Mahape, Navi Mumbai, India |
| 20 Feb, 2025 | NSE India | Cipla Limited has informed the Exchange regarding ''USFDA inspection at analytical testing facility of Sitec in Mahape, Navi Mumbai, India''. |
| 20 Feb, 2025 | NSE India | Cipla Limited has informed the Exchange about Product launch |
| 20 Feb, 2025 | BSE India | Company has received final approval from USFDA for NDA submitted for Nilotinib Capsules 50, 150 and 200 mg on 19th February, 2025 |
| 19 Feb, 2025 | NSE India | Cipla Limited has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL |
| 18 Feb, 2025 | NSE India | Cipla Limited has informed the Exchange about General Updates |
| 18 Feb, 2025 | NSE India | Cipla Limited has informed the Exchange about Investor Presentation |
| 13 Feb, 2025 | NSE India | CIPLA LIMITED has informed the Exchange regarding Allotment of Securities |
| 13 Feb, 2025 | BSE India | In compliance with regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that the Operations and Administration Committee of the Company on 13th February, 2025 has allotted 901 equity shares of INR 2/- each pursuant to exercise of Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company |
| 13 Feb, 2025 | NSE India | Cipla Limited has informed the Exchange regarding Allotment of 901 Shares. |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 07 Jan, 2025 | 28 Jan, 2025 |
| Quarterly Results | -- | 03 Oct, 2024 | 29 Oct, 2024 |
| Quarterly Results | -- | 05 Jul, 2024 | 26 Jul, 2024 |
| Audited Results & Final Dividend | -- | 08 Apr, 2024 | 10 May, 2024 |
| Quarterly Results | -- | 21 Jan, 2024 | 25 Jan, 2024 |
| Quarterly Results | (Revised) | 21 Jan, 2024 | 22 Jan, 2024 |
| Quarterly Results | -- | 05 Oct, 2023 | 27 Oct, 2023 |
| Quarterly Results | -- | 05 Jul, 2023 | 26 Jul, 2023 |
| Audited Results & Final Dividend | -- | 13 Apr, 2023 | 12 May, 2023 |
| Quarterly Results | -- | 30 Dec, 2022 | 25 Jan, 2023 |
Share Holding Pattern
| Owner Name | Dec, 2024 | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
|---|
About Cipla
Cipla is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1935PLC002380 and registration number is 002380. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 16574.34 Cr. and Equity Capital is Rs. 161.47 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Cipla Group
Founded
1935
Managing Director
Mr. Umang Vohra
NSE Symbol
CIPLA
Cipla Management
| Name | Designation |
|---|---|
| Dr. Y K Hamied | Chairman |
| Mr. M K Hamied | Vice Chairman |
| Mr. Umang Vohra | Managing Director & Global CEO |
| Ms. Samina Hamied | Non Exe.Non Ind.Director |
| Mr. S Radhakrishnan | Non Exe.Non Ind.Director |
| Mr. Ashok Sinha | Independent Director |
| Mr. P R Ramesh | Independent Director |
| Mr. Robert Stewart | Independent Director |
| Dr. Mandar Vaidya | Independent Director |
| Mr. Adil Zainulbhai | Independent Director |
| Ms. Punita Lal | Independent Director |
| Dr. Balram Bhargava | Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| SunPhrmInds | ₹4,46,576.22 | ₹1,643.75  ₹1,669.30(-1.53%) | ₹1,249.800 - ₹1,960.200 |
| Divis Labora | ₹1,56,123.40 | ₹5,757.05 ₹5,978.30(-3.70%) | ₹3,350.050 - ₹6,448.750 |
| Cipla | ₹1,21,675.13 | ₹1,475.75 ₹1,479.70(-0.27%) | ₹1,240.700 - ₹1,702.000 |
| ManKind Phar | ₹1,18,478.90 | ₹2,327.75 ₹2,348.45(-0.88%) | ₹1,910.100 - ₹3,050.000 |
| DrReddysLab | ₹1,15,939.04 | ₹1,151.80 ₹1,170.95(-1.64%) | ₹1,104.690 - ₹1,420.200 |
FAQs on Cipla
What is the share price of Cipla?
The share price of Cipla on 21 Feb, 2025 is ₹ 1,472.00.
What is 52W high and 52W low share price of Cipla?
The highest and lowest 52W share prices of Cipla are ₹ 1702.000 and ₹ 1240.700
What is the market cap of Cipla?
The market capitalization of Cipla as of 21 Feb, 2025 is ₹ 1,19,183.77 Crores
What is the P/E ratio of Cipla?
The current P/E ratio of Cipla as of 21 Feb, 2025 is 43.99
What is the PB ratio of Cipla?
The PB ratio of Cipla as of 21 Feb, 2025 is 4.45
Top Gainers
948IHFL26I
IBHFL NCD186
₹845.00
₹705.00 (0.20%)
GREAVESCOT
Greaves
₹281.85
₹234.90 (0.20%)
ASHSI
Ashirwd Stl
₹45.66
₹38.05 (0.20%)
CAPRO
Caprola.Chem
₹62.40
₹52.00 (0.20%)
Top Losers
DHANBANK
Dhanalak.Bnk
₹32.19
₹35.97 (-0.11%)
08MPD
08MPD
₹8.66
₹9.62 (-0.10%)
BALTE
BalurghtTran
₹27.13
₹31.24 (-0.13%)
DARSHANORNA
Darshan Orna
₹4.57
₹5.07 (-0.10%)
Market Indices
Sensex
₹78,699.07
₹78,472.48 (0.00%)